AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NOXOPHARM LTD

0.060

0.000

Volume:- -

Turnover:2.56K

Market Cap:18.43M

PE:-3.18

High:0.060

Open:0.060

Low:0.060

Close:0.060

52wk High:0.135

52wk Low:0.043

Shares:307.24M

Float Shares:195.51M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.019

EPS(LYR):-0.017

ROE:-343.56%

ROA:-54.04%

PB:-16.35

PE(LYR):-3.59

Loading ...

Overview Company News Filings

We Think Noxopharm (ASX:NOX) Has A Fair Chunk Of Debt

Simply Wall St.

BUZZ-Australia's Noxopharm hits two-week high on autoimmune clinical trial progress

Noxopharm Ltd-Heracles Clinical Trial Update 5

THOMSON REUTERS

ASX Small-Cap Stocks to Watch

MT Newswires Live

BRIEF-Noxopharm Receives NSW Government Grant For UNSW Collaboration

ASX Small-Cap Stocks to Watch

MT Newswires Live

Noxopharm Ltd - Nsw Government Grant for Unsw Collaboration

THOMSON REUTERS

BRIEF-Noxopharm Says First US Patent For Sofra Technology Platform

Noxopharm Ltd - First US Patent for Sofra Technology Platform

THOMSON REUTERS

Noxopharm Says Holder of Existing Convertible Notes Green Light Maturity Date Extension, Shares Fall 5%

MT Newswires Live

Noxopharm Completes Final Single-Dose Group in Autoimmune Diseases Drug Candidate Trial, Shares Fall 6%

MT Newswires Live

Noxopharm Ltd-Heracles Clinical Trial Update 2

THOMSON REUTERS

Noxopharm Says US Biotechnology Company Finds 'Encouraging' Sofra Results; Shares Up 9%

MT Newswires Live

BUZZ-Australia's Noxopharm rises on successful first dose for autoimmune disease drug

Noxopharm Ltd-Heracles Clinical Trial - Update 1

THOMSON REUTERS

BUZZ-Australia's Noxopharm rises on autoimmune drug trial initiation

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NOX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NOX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NOX.AU\",,,,,undefined,":{"symbol":"NOX.AU","market":"AU","secType":"STK","nameCN":"NOXOPHARM LTD","latestPrice":0.06,"timestamp":1773102923916,"preClose":0.06,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"NOXOPHARM LTD","floatShares":195506720,"shares":307237950,"eps":-0.018848,"marketStatus":"Trading","change":0,"latestTime":"03-10 11:35:23 AEDT","open":0.06,"high":0.06,"low":0.06,"amount":2556.21594834,"amplitude":0,"askPrice":0.066,"askSize":39985,"bidPrice":0.06,"bidSize":6975,"shortable":3,"etf":0,"ttmEps":-0.018848,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773118800000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.06,"openAndCloseTimeList":[[1773097200000,1773118800000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NOX.AU","preClose":0.061,"auctionPrice":0.061,"auctionVolume":6009,"auction":3,"marketStatus":"盘后竞价","timestamp":1773032400595}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NOX.AU\",,,,,undefined,":{"symbol":"NOX.AU","floatShares":195506720,"roa":"-54.04%","roe":"-343.56%","lyrEps":-0.016712,"shares":307237950,"dividePrice":0,"high":0.06,"amplitude":0,"preClose":0.06,"low":0.06,"week52Low":0.043,"pbRate":"-16.35","psRate":"5.43","week52High":0.135,"institutionHeld":0,"latestPrice":0.06,"committee":-0.702939,"eps":-0.018848,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.018848,"open":0.06,"prevYearClose":0.093,"prevWeekClose":0.061,"prevMonthClose":0.066,"prevQuarterClose":0.093,"fiveDayClose":0.068,"twentyDayClose":0.07,"sixtyDayClose":0.099,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NOX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NOX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NOX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589585176","title":"We Think Noxopharm (ASX:NOX) Has A Fair Chunk Of Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2589585176","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589585176?lang=en_us&edition=fundamental","pubTime":"2025-12-05 05:38","pubTimestamp":1764884290,"startTime":"0","endTime":"0","summary":"The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nox/noxopharm-shares/news/we-think-noxopharm-asxnox-has-a-fair-chunk-of-debt","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nox/noxopharm-shares/news/we-think-noxopharm-asxnox-has-a-fair-chunk-of-debt","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","EBIT","NOX.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2588099272","title":"BUZZ-Australia's Noxopharm hits two-week high on autoimmune clinical trial progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2588099272","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588099272?lang=en_us&edition=fundamental","pubTime":"2025-12-03 11:39","pubTimestamp":1764733183,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Noxopharm hits two-week high on autoimmune clinical trial progress** Shares of Australia's Noxopharm NOX.AX rise 2.1% to A$0.099, their highest level since November 17** The biotechnology company says the first multiple-dose cohort in the in-human trial for co's autoimmune diseases drug, SOF-SKN, has been successfully completed, bringing co to the final second and final stage of the trial ** Safety Steering Committee has determined the treatment to be safe and well tolerated, with no clinically relevant issues found, co adds** Stock up 6.5%, YTD   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL6N3X907R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","BK7508","NOX.AU"],"gpt_icon":0},{"id":"2588066025","title":"Noxopharm Ltd-Heracles Clinical Trial Update 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2588066025","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588066025?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:21","pubTimestamp":1764710499,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUE4KLTYP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NOX.AU","BK7508","BK7067","BK7501"],"gpt_icon":0},{"id":"2584691997","title":"ASX Small-Cap Stocks to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2584691997","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584691997?lang=en_us&edition=fundamental","pubTime":"2025-11-17 07:48","pubTimestamp":1763336888,"startTime":"0","endTime":"0","summary":"Investors are likely to keep an eye on the following small-cap stocks listed on the Australian Securities Exchange.Canadian Phosphate (ASX:CP8)Canadian Phosphate welcomed a decision by the US Departme","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7504","BK7508","NMT.AU","BK7507","CP8.AU","NGY.AU","BK7020","BK7095","BK7501","NOX.AU","BK7506","BPM.AU","BK7142","BK7067"],"gpt_icon":0},{"id":"2582387846","title":"BRIEF-Noxopharm Receives NSW Government Grant For UNSW Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2582387846","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582387846?lang=en_us&edition=fundamental","pubTime":"2025-11-11 09:08","pubTimestamp":1762823316,"startTime":"0","endTime":"0","summary":"BRIEF-Noxopharm Receives NSW Government Grant For UNSW CollaborationNov 11 (Reuters) - Noxopharm Ltd NOX.AX:NSW GOVERNMENT GRANT FOR UNSW COLLABORATIONFurther company coverage: NOX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nFWN3WM2BH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NOX.AU","BK7501","BK7067","BK7508"],"gpt_icon":0},{"id":"2582381325","title":"ASX Small-Cap Stocks to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2582381325","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582381325?lang=en_us&edition=fundamental","pubTime":"2025-11-11 07:46","pubTimestamp":1762818394,"startTime":"0","endTime":"0","summary":"Investors are likely to keep an eye on the following small-cap stocks listed on the Australian Securities Exchange.Activeport Group (ASX:ATV)Activeport Group launched its network-to-network interconne","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","NOX.AU","ATV.AU","XJO.AU","BK7501","BK7511","CMO.AU","BK7095","BK7016","BK7508","BK7135","BK7502","BK7096","NAB.AU","CZN.AU","CAN.AU","XAO.AU","BK7067"],"gpt_icon":0},{"id":"2582881143","title":"Noxopharm Ltd - Nsw Government Grant for Unsw Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2582881143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582881143?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:26","pubTimestamp":1762809965,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nFWN3WM2BH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","NOX.AU","BK7501","BK7508"],"gpt_icon":0},{"id":"2577828533","title":"BRIEF-Noxopharm Says First US Patent For Sofra Technology Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2577828533","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577828533?lang=en_us&edition=fundamental","pubTime":"2025-10-22 09:08","pubTimestamp":1761095315,"startTime":"0","endTime":"0","summary":"BRIEF-Noxopharm Says First US Patent For Sofra Technology PlatformOct 22 (Reuters) - Noxopharm Ltd NOX.AX:FIRST US PATENT FOR SOFRA TECHNOLOGY PLATFORMFurther company coverage: NOX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nFWN3W226V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","BK7067","NOX.AU"],"gpt_icon":0},{"id":"2577800425","title":"Noxopharm Ltd - First US Patent for Sofra Technology Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2577800425","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577800425?lang=en_us&edition=fundamental","pubTime":"2025-10-22 05:26","pubTimestamp":1761081965,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nFWN3W226V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","NOX.AU","BK7501"],"gpt_icon":0},{"id":"2569765446","title":"Noxopharm Says Holder of Existing Convertible Notes Green Light Maturity Date Extension, Shares Fall 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569765446","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569765446?lang=en_us&edition=fundamental","pubTime":"2025-09-23 12:20","pubTimestamp":1758601237,"startTime":"0","endTime":"0","summary":"Noxopharm  said that the holders of its existing convertible notes, with a total aggregate note face value of AU$2.6 million, approved the extension of the maturity date of their convertible notes to Jan. 2, 2027, according to a Tuesday Australian bourse filing.The noteholders will be paid accrued interest of AU$327,000 in aggregate on the convertible notes in cash for the period ending Jan. 2, 2026, with the interest accruing from Jan. 2, 2026, capitalized daily until maturity.The extension will allow the company to access rebate funds of around AU$2.8 million from the Australian Federal Government's Research and Development Tax Incentive Scheme for the financial year ended June 30.It entered into an unsecured loan agreement with 4F Investments, which is owned and controlled by Noxopharm Chairman Fred Bart, for a AU$1.25 million unsecured loan to Noxopharm. Interest will be payable at 12% per annum on the loan capitalized daily until maturity.The firm's shares fell 5% in recent tradin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7501","XJO.AU","XAO.AU","BK7508","XKO.AU","NOX.AU"],"gpt_icon":0},{"id":"2565757029","title":"Noxopharm Completes Final Single-Dose Group in Autoimmune Diseases Drug Candidate Trial, Shares Fall 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2565757029","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565757029?lang=en_us&edition=fundamental","pubTime":"2025-09-08 13:46","pubTimestamp":1757310418,"startTime":"0","endTime":"0","summary":"Noxopharm  said the fourth and last single-dose group of SOF-SKN, a drug candidate for autoimmune diseases like cutaneous lupus erythematosus, was completed in the HERACLES trial, according to a Monday Australian bourse filing.The safety steering committee determined the dose level to be safe and tolerable, with no clinically relevant issues identified.The study aims to evaluate the safety and tolerability profile of SOF-SKN by testing it at four different concentrations. Each group is scheduled to take around two weeks due to several tests, including electrocardiograms, physical exams, participant questionnaires, and numerous blood tests.The firm's shares fell 6% in recent trading on Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","NOX.AU","BK7501"],"gpt_icon":0},{"id":"2558880682","title":"Noxopharm Ltd-Heracles Clinical Trial Update 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2558880682","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558880682?lang=en_us&edition=fundamental","pubTime":"2025-08-11 06:31","pubTimestamp":1754865078,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250810:nTUE3HBR5K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NOX.AU","BK7501","BK7508","BK7067"],"gpt_icon":0},{"id":"2557635104","title":"Noxopharm Says US Biotechnology Company Finds 'Encouraging' Sofra Results; Shares Up 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557635104","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557635104?lang=en_us&edition=fundamental","pubTime":"2025-08-05 12:03","pubTimestamp":1754366590,"startTime":"0","endTime":"0","summary":"Noxopharm  said US-based Tezcat Biosciences found \"encouraging\" results in its pre-clinical in vitro studies of assets from the Sofra technology platform, according to a Tuesday filing with the Australian bourse.Tezcat Biosciences conducted a series of studies, which demonstrated that the company's oligonucleotides can be attached to Tezcat's delivery system to create a new drug candidate with strong anti-inflammatory activity, the filing said.The company has partnered with Tezcat since 2024, and plans are underway to undertake further studies in animal models, per the filing.Noxopharm shares rose 9% in afternoon trade on Tuesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","NOX.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2554740156","title":"BUZZ-Australia's Noxopharm rises on successful first dose for autoimmune disease drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2554740156","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554740156?lang=en_us&edition=fundamental","pubTime":"2025-07-28 12:24","pubTimestamp":1753676674,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Noxopharm rises on successful first dose for autoimmune disease drug** Shares of Noxopharm Ltd NOX.AX rise as much as 29.3% to A$0.097, hitting their highest level since February 14** Stock set for best session since mid-July** Biotech firm says first dose of autoimmune disease drug SOF-SKN found safe and tolerable ** Says, trial, aimed at checking the concentration at which the drug is tolerable, will proceed to next cohort of participants who will receive a higher dose** Around 683,067 shares change hands, compared with 30-day avg volume of about 280,207 shares** Session brings YTD gains to 4.3%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nL4N3TP080:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NOX.AU","BK7067","BK7501","BK7508"],"gpt_icon":0},{"id":"2554746402","title":"Noxopharm Ltd-Heracles Clinical Trial - Update 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2554746402","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554746402?lang=en_us&edition=fundamental","pubTime":"2025-07-28 07:40","pubTimestamp":1753659607,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250727:nTUE4LSNL4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","NOX.AU","BK7067"],"gpt_icon":0},{"id":"2551111551","title":"BUZZ-Australia's Noxopharm rises on autoimmune drug trial initiation","url":"https://stock-news.laohu8.com/highlight/detail?id=2551111551","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551111551?lang=en_us&edition=fundamental","pubTime":"2025-07-16 11:44","pubTimestamp":1752637477,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Noxopharm rises on autoimmune drug trial initiation** Shares of Noxopharm NOX.AX rise nearly 46% to A$0.07, their biggest pct gain since October 4, 2023** Stock hits highest level since June 6** Biotech co says first dose of SOF-SKN, a drug candidate for autoimmune diseases was administered to trial participant** Around 422,086 shares traded, 2.2x the 30-day avg** YTD, shares down 24.7%, including today's move  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nL4N3TD09E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","BK7508","NOX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}